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Retinoic acid (RA) signaling is important to normal development. However, the function of the different RA
receptors (RARs)—RARa, RARb, and RARg—is as yet unclear. We have used wild-type and transgenic zeb-
rafish to examine the role of RARg. Treatment of zebrafish embryos with an RARg-specific agonist reduced
somite formation and axial length, which was associated with a loss of hoxb13a expression and less-clear
alterations in hoxc11a or myoD expression. Treatment with the RARg agonist also disrupted formation of tissues
arising from cranial neural crest, including cranial bones and anterior neural ganglia. There was a loss of Sox 9-
immunopositive neural crest stem/progenitor cells in the same anterior regions. Pectoral fin outgrowth was
blocked by RARg agonist treatment. However, there was no loss of Tbx-5-immunopositive lateral plate meso-
dermal stem/progenitor cells and the block was reversed by agonist washout or by cotreatment with an RARg
antagonist. Regeneration of the caudal fin was also blocked by RARg agonist treatment, which was associated
with a loss of canonical Wnt signaling. This regenerative response was restored by agonist washout or cotreatment
with the RARg antagonist. These findings suggest that RARg plays an essential role in maintaining stem/
progenitor cells during embryonic development and tissue regeneration when the receptor is in its nonligated state.
Introduction
Retinoic acid (RA) is a critical regulator of cell prolif-eration, cell differentiation, axis formation, and organo-
genesis in developing embryos [1,2]. RA can exist in three
lipophilic forms, that is, all-trans RA, 9-cis RA, and 13-cis
RA, all of which readily cross cell membranes to bind to a
cytoplasmic carrier protein known as the cellular retinoic acid
binding protein (CRABP) [3,4]. Once bound to CRABP, RA is
translocated into the nucleus where it transfers to one of three
types of the known RA receptors (RARs), termed RARa,
RARb, and RARg [5]. These RARs form dimers with the
retinoid X receptor (RXR) and RA ligation of the RAR:RXR
complex upregulates expression of those genes that contain an
RA response element (RARE). The mechanisms that affect
such RA-driven alterations in gene expression include epige-
netic changes and recruitment of coactivator proteins to the
RAR:RXR of responsive genes [6]. However, RARs also
function when not ligated to RA to repress gene expression. In
this situation, nonligated RARs form an RAR-corepressor-
histone deacetylase complex on RARE. This complex has
been proposed to play a key role in the repression of gene
expression in undifferentiated stem cells during early devel-
opment [7]. Indeed, Koide et al. have shown that repression of
gene expression is a key function of nonligated RAR during
the regulated development of the head region in mice [8].
The specific roles of each of the different isoforms of RARs
in regulating the response of stem/progenitor cells to RA during
development remain largely unknown. Despite potential for
functional redundancy, there is likely to be significant differ-
ences in RAR function because expression levels of RAR
isoforms vary both temporally and spatially [9,10]. Gene-
knockout experiments of RARs in mice support differential
function of RARs. For example, RARa-knockout mice ex-
hibit no discernable phenotype [11] and RARb-knockout mice
have ocular defects and reduced body weight [12], while
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knockout of RARc results in several severe developmental
defects, including growth deficiency, cartilage dysmorpho-
genesis, and vertebrate malformations [13]. However, as RARs
can function both to repress as well as activate targeted gene
expression through respective engagement by RAR of core-
pressor or coactivator proteins, the use of gene-knockout
methods to determine the physiological role of RARs is prob-
lematic. For example, the deletion of RAR may result in release
of corepressor proteins bound to the RAR when non-RA ligated
and the activity of these released corepressors may in them-
selves produce developmental defects, at least in mammals
[14]. Moreover, Williams et al. (2009) suggested that the ability
of RARg, in particular, to repress gene expression is required
for normal skeletal development of long bones. Therefore, in
order to fully understand the importance of RAR in regulating
gene activity, there are advantages to the use of specific ago-
nists and antagonists for each of the different RARs [14].
In zebrafish, there are two major RARs, RARa and RARg
[10]. RARc expression is restricted in early zebrafish em-
bryos to mesodermal and neural crest stem/progenitor cells,
in the head area, in the lateral plate mesoderm, and in the
presomitic mesoderm of the tail bud [9,10]. Retinaldeyhyde
dehydrogenase (RALDH), which is responsible for synthe-
sizing RA, is not expressed within these areas [16,17].
Further, a transgenic reporter line indicating the presence of
endogenous RA has shown that RA is not present in the tail
bud, which is one of the locations for RARc expression [18].
These nonoverlapping expression patterns of RARc and
RALDH suggest that RARg does not function during de-
velopment to activate RA-responsive genes. Instead, a lack
of RARg-dependent transcriptional activity may be impor-
tant and RARg may play a key role in repressing gene ex-
pression in its nonligated state.
We hypothesized that if RARg functions in its nonligated
state to repress gene expression, then engaging an RARg-spe-
cific ligand will result in aberrant transcriptional activity of
genes that by default should be switched ‘‘off.’’ In other words,
cells or tissues expressing RARc that are affected by treatment
with an RARg agonist may be those wherein RARg plays an
important gene repressive activity. To investigate this possibility
during embryonic development, this study has examined the
effects of RARg-specific agonist treatments in zebrafish larvae
[15]. Our findings have shown that treatment with an RARg
agonist has major deleterious consequences on the development
of tissues that derive from neural crest and mesoderm, and also
on caudal fin regeneration. The effects of the RARg agonist
treatments on the pectoral and caudal fin were reversed by
washout of the agonist or cotreatment with an RARg-specific
antagonist. We have also used transgenic reporter zebrafish lines
to identify downstream pathways regulated by RARg activity,
which paradoxically showed decreased expression of some hox
genes and canonical Wnt signaling. These findings provide ev-
idence that RARg plays a critical role to maintain stem/pro-
genitor cells during normal embryonic development and tissue
regeneration, which depends on its ligation status.
Materials and Methods
Zebrafish husbandry
Stocks of the wild-type AB strain of zebrafish were
maintained in the fish unit of the Biomedical Research fa-
cility in Aston University according to U.K. Home Office
guidelines. The unit had a 14/10 h day/night cycle according
to zebrafish husbandry guidelines [19]. Following breeding,
zebrafish embryos were kept in an incubator at 28C in petri
dishes (SLS, Hessle, UK) in a 4 mL solution of Hank’s so-
lution (Molekula, Dorset, UK) or E3 fish media. Experi-
ments using transgenic reporter fish were performed at the
National Institute of Genetics (NIG) in Mishima, Japan,
with husbandry according to NIG institutional guidelines
[20]. Two transgenic hox gene reporter fish lines of the
Gal4-UAS system were used, namely, the hoxc11a and
hoxb13a lines [21]. In these transgenic fish, the gene trap
and enhancer trap constructs are integrated within hoxc11a
and hoxb13a genes, respectively. Therefore, Gal4FF ex-
pression is likely to recapitulate that of the endogenous
genes [22]. The transgenic zebrafish reporter line HGn39D
was used to visualize the lateral line [23]. The transgenic
zebrafish reporter line Tcf:mini-p was used to visualize
canonical Wnt signaling [24], which was kindly provided by
Dr. Ishitani (Kyushu University). For Gal4-UAS breeding,
either male or female adult zebrafish of the Gal4 line was
crossed with UAS-GFP reporter zebrafish as pair-wise
crossings in breeding tanks. The male and female zebrafish
were separated using a barrier the evening before the actual
day of breeding. The barrier was removed on the following
morning to allow male and female mating and fertilized
eggs were collected within 30–60 min of this using a
strainer.
RARc reagents: preparation and treatment
protocols
The RARg-specific agonist (AGN205327) and antagonist
(AGN205728) [15] were kept as 10 mM stock solutions dis-
solved in 50% dimethyl sulfoxide (DMSO) and 50% meth-
anol. These stocks were diluted with 100% DMSO to give a
working stock solution at 100mM according to previously
published studies [25]. These working stocks were then fur-
ther diluted with Hank’s solution or E3 media to the final
doses used for the treatments of zebrafish embryos as given in
‘‘Results’’ section. A control solution of a 50%:50% DMSO:
methanol-carrier-alone stock further diluted into 100% DMSO
and then into Hank’s or embryo media was prepared using
the exact dilutions that were used for the RARg reagents.
Following treatment of zebrafish embryos by immersion in
E3 media supplemented with the RARg reagents or carrier
alone at 4 hours postfertilization (hpf) (or at other times as
indicated in ‘‘Results’’ section), the treated and control
embryos were incubated at 28C [19]. Zebrafish embryos were
treated with the RARg agonist at 4 hpf because the agonist is
not subjected to degradation and RARc expression is de-
tected at the 40% epiboly stage, which is around 5 hpf [10].
In situ hybridization and immunolocalization
protocols
In situ hybridization for myoD expression was performed
according to previously published methods [26]. In brief,
zebrafish embryos treated with the RARg agonist (at 4 hpf)
and control embryos were harvested at 22 hpf and fixed in
4% paraformaldehyde (PFA) at 4C overnight, before de-
hydrating in 100% methanol, also at 4C overnight. The
embryos were then serially rehydrated through decreasing
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alcohols (100%–25% methanol) finally to phosphate-
buffered saline (PBS) alone. The rehydrated embryos were
digested with proteinase K (10mg/mL; Sigma, St. Louis,
MO) for 10 min. In situ hybridization was performed by
incubating the embryos in hybridization mix solution at
70C for 5 h, prior to a further overnight incubation at 70C
with the myoD probe (ZFIN:ZDB-GENE-980526-561).
Following a series of washes in sodium citrate solutions and
then PBS, the embryos were incubated overnight at 4C
with anti-DIG-alkaline phosphatase antibody specific for the
myoD probe (Invitrogen, Carlsbad, CA), and, following
further washes in PBS, immunopositivity was revealed
using staining solutions of nitro blue tetrazolium (Sigma)
and 5-bromo 4-chloro 3-indolyl phosphate (Sigma). The
stained embryos were then transferred to glycerol (Mole-
kula) for microscopy and imaging.
Immunolocalization was performed for the muscle mar-
ker a-actinin, the neural crest marker Sox9, and the lateral
plate mesoderm marker Tbx5, by adapting previously pub-
lished methods [27]. In brief, RARg-agonist-treated and
control embryos were fixed in 4% PFA at 4C overnight at
the time points indicated in ‘‘Results’’ section and then
washed repeatedly in PBS-Tween (PBS-T; 90%:10%) be-
fore an enzymatic digestion with collagenase (1 mg/mL;
Sigma) for 75 min at 37C. The embryos were then incu-
bated with antibodies specific for a-actinin (1/100 dilution
in PBS-T; Sigma) or Sox9 (1/100 dilution in PBS-T, Clone
ab76997; Abcam Ltd., Cambridge, UK) or Tbx5 (Genetix,
Irvene, CA) at 4C overnight. Embryos were then washed
repeatedly in PBS-T prior to incubation with Alexa 594-
conjugated anti-mouse antibodies for a-actinin or Sox9 (1/
250 dilution in PBS-T; Invitrogen Ltd.) at 4C overnight,
washing again in PBS-T, and then mounted in glycerol for
microscopy and image capture. For Tbx5 immunolocaliza-
tion, embryos were similarly washed repeatedly in PBS-T
after incubation with the primary antibodies, after which
immunopositivity was revealed using biotin-anti-rabbit
secondary antibodies (1/400 in PBS-T; Vector Labs, Pe-
terborough, UK) followed by further washes and incubation
with streptavidin-linked fluorescein isothiocyanate (FITC)
(1/50 in PBS-T; Vector Labs), adapting methods previously
described [28].
Alizarin red staining for bone formation
Alizarin red staining was performed to examine the
presence of bone by adapting previously published methods
[25]. In brief, RARg-agonist-treated and control embryos
were euthanized at 5 days postfertilization (dpf) and fixed in
4% PFA at 4C overnight and then washed in PBS-T prior to
staining in a solution of alizarin red (96% of 0.5% potassium
hydroxide:4% of 0.1% alizarin red S; Molekula) for 3 h at
room temperature. After staining, the embryos were washed
and mounted in glycerol prior to microscopy and image
capture.
Image capture and analysis
Phase-contrast or bright-field digitized images were cap-
tured using a Nikon DXM1200 camera attached to a Nikon
SMZ745T stereomicroscope, a Leica DFX 300FX camera
attached to a Leica MZ 16FA stereomicroscope, or a Je-
noptik camera attached to a Ceti inverted microscope. A
Leica DFX 300FX camera, attached to a Leica MZ 16FA
stereomicroscope, was also used to capture fluorescence im-
ages of the transgenic zebrafish embryos and of a actinin-
immunostained embryos. Laser scanning confocal microscopy
was performed with the Leica Microsystems DM6000B-
SP57CS confocal system to generate z stacks of Sox9- and
Tbx5-immunostained zebrafish embryos. These were then
converted into 3 dimensional (3D) projected images of the
entire ventral-dorsal or lateral aspects. The projected images
of Sox9-immunostained zebrafish embryos were used to
quantify the number of Sox9-immunopositive cells present
in the total head region that was anterior from the anterior
aspect of the otic vesicle. Phase-contrast digitized images
were captured at low magnification (4 · lens) and these
images were analyzed to determine the embryo length along
the antero-posterior axis using Image J software.
Caudal fin transection
The AB strain or Tcf:mini-p transgenic zebrafish embryos
at 2 or 3 dpf, respectively, were anesthetized with 0.4%
Tricaine (Sigma) and then placed on a glass slide and the
caudal fin was transected using a thin scalpel blade (SLS).
The embryos were then transferred to fresh Hank’s saline or
E3 media in an incubator at 28.5C for those periods of fin
regrowth indicated in ‘‘Results’’ section. The embryos were
treated with the RARg agonist (10 nM) or carrier alone
immediately following caudal fin transection. In some ex-
periments, the AB strain embryos were treated with an
RARg-specific antagonist at 3 dpf (following RARg agonist
treatment at 2 dpf) or subjected to washout of the RARg
agonist at 3 dpf.
Statistical analysis
Data were evaluated for normal distribution using the
D’Agostino and Pearson omnibus normality test. One-way
or two-way analysis of variance (ANOVA) was used to
assess the relationships between treatment of zebrafish em-
bryos with different concentrations of the RARg agonist and
fish length or the growth of treated versus control embryos
over time, with post hoc analysis. Student’s paired t-tests or
Mann–Whitney U tests were used to examine differences
between treatment versus control groups for hox gene ex-
pression or the prevalence of Sox9-immunopositive cells,
according to whether the data were normally or not normally
distributed, respectively. All statistical analyses were per-
formed using GraphPad Prism software. Values were con-
sidered statistically significant, as indicated in ‘‘Results’’
section, at P£ 0.05 (*). Unless otherwise indicated all data
have been presented as means– standard deviations where a
minimum of n= 3 procedures were performed for all experi-
ments. The total number of embryos in these experiments that
were pooled and analyzed have been shown in figure legends.
Results
Treatment of zebrafish embryos with the RARc
agonist inhibited antero-posterior growth
and decreased somite formation
Treatment of zebrafish embryos at 4 hpf with the RARg
agonist was associated with clear morphological differences
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during development, with the main difference being a re-
duced antero-posterior axis length (Fig. 1A). The reduction
in fish length was RARg agonist dose dependent. Treatment
of embryos with 1 nM RARg agonist had no obvious effects
on zebrafish growth while treatments with the RARg agonist
at 80 nM (or above) caused severe truncation (Fig. 1B). The
RARg-agonist-treated embryos also developed cardiac
edema and, beyond 3 dpf, embryos treated with the higher
doses of the RARg agonist lost viability (data not shown).
Therefore, all further analyses were performed using the
RARg agonist at 10 nM, which was not lethal. Changes in
the antero-posterior length of embryos treated with 10 nM
RARg agonist were most markedly affected from 2 dpf
onward, such that the treated embryos were significantly
shorter than the control embryos at 3–5 dpf (Fig. 1C).
Somite formation was observed using an indicator trans-
genic fish line (hspGFF55B), which has green fluorescent
protein (GFP) expression in its somites and heart [21]. At
3 dpf, the number of somites present in RARg agonist
(10 nM)–treated embryos in this transgenic fish line was
consistently observed to be 25, which is 5 fewer than the 30
somites that were observed in the control transgenic em-
bryos at the same stage of development (and is the normal
somite number in adult zebrafish) [29] (Fig. 2A). In situ
hybridization for myoD, which specifies myocyte differen-
tiation, as well as immunolocalization for the myocyte
marker a-actinin, was performed to further assess somite
formation. Although a somewhat weaker level of myoD
expression was seen in the anterior regions of the RARg-
agonist-treated embryos compared with control embryos
(Fig. 2B, C), this was not associated with a clear inhibition
in myocyte formation as delineated by a-actinin immuno-
reactivity (Fig. 2D, E). Further, the pattern of a-actinin
immunoreactivity confirmed that there was the same reduced
number of somites (ie, 25 somites at 3 dpf) in the RARg-
agonist-treated embryos compared with control embryos (ie,
30 somites at 3 dpf). Therefore, treatment with an RARg
agonist was associated with decreased axial length and a
specific reduction in the formation of somites without a
uniform inhibition of myocyte differentiation.
Differential hoxc11a and hoxb13a expression
patterns demonstrated that the reduced
antero-posterior length in RARc-agonist-treated
zebrafish embryos was associated with a loss
of posterior tissues
Precise expression of the hox gene family is necessary for
normal antero-posterior axis formation in vertebrates [30].
Transgenic fish lines, SAGFF155A and hspGFFDMC28B,
were used to indicate the expression patterns of hoxc11a and
hoxb13a in RARg-agonist-treated versus control embryos
(Fig. 3). As shown, hoxc11a was expressed from near the
anal region to the caudal regions in the RARg-agonist-
treated and control embryos at 2 dpf (Fig. 3A), although the
cranial start of hoxc11a expression was three to four somites
more posterior in the RARg-agonist-treated embryos. In
sharp contrast, the expression of hoxb13a at 2 dpf (Fig. 3B)
was only seen in the most posterior caudal region of the
control embryos, as well as in the anal region, whereas no
hoxb13a expression was seen in the RARg-agonist-treated
embryos. These patterns of expression were consistent in all
treated and control zebrafish embryos throughout their de-
velopment. The distance from the anterior end of the head to
the anal regions of either the wild-type (AB strain; see Fig.
1A) or the hox gene reporter fish lines was similar in the
RARg-agonist-treated and control embryos. Conversely,
there was a marked decrease in the distance from the anal
regions to the most caudal end of the RARg-agonist-treated
embryos compared with control embryos. Hence, these
differential patterns of hox gene expression indicate that
RARg agonism adversely prevented the formation of the
most posterior somites and caudal fin, which was associated
with a complete loss of hoxb13a expression.
Hoxb13a expression and growth of the caudal
fin were rescued by washout of the RARc agonist
or additional treatment with the RARc antagonist
To examine whether the loss of hox gene expression after
RARg agonist treatment may have been due to irreversible
teratogenic effects early in the development of the zebrafish,
rather than being targeted toward the hox gene pathway, we
examined whether hoxb13a expression returned following
treatment with the RARg agonist at 4 hpf and then either
washout of the RARg agonist at 23 hpf or cotreatment with
FIG. 1. Treatment of embryonic zebrafish at 4 h post-
fertilization (hpf) with a retinoic acid receptor g (RARg)
agonist was associated with a dose-dependent decrease in
the antero-posterior length and slower axial growth. (A) A
representative phase-contrast microscopy image showing
the left lateral view of RARg agonist (10 nM)–treated and
control AB strain zebrafish embryos at 3 days post-
fertilization (dpf). The RARg-agonist-treated embryo length
was markedly shorter than the control. Cardiac edema was
also evident (arrow). Scale bar represents 250mm. (B) There
was a significant relationship between RARg agonist doses
and the axial length of zebrafish embryos at 3 dpf, with a
significantly lesser length versus control at doses of 10 nM
and above [P£ 0.0001; analysis of variance (ANOVA) with
post-hoc analysis; data shown as means– standard deviations
(SDs), pooled from three independent experiments]. (C)
RARg agonist (10 nM)–treated zebrafish embryos had slower
growth rates than control embryos, most markedly from 3
to 5 dpf (data shown as means–SDs, from n= 10 RARg-
agonist-treated versus n= 10 control fish).
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the RARg antagonist, also at 23 hpf. As shown (Fig. 4), no
hoxb13a expression was observed in the anal region and the
most posterior region of the tail or caudal fin in RARg-
agonist-treated embryos at 5 dpf (Fig. 4A). In contrast, in the
embryos that were treated with the RARg agonist at 4 hpf
and then subsequently treated with the RARg antagonist at
23 hpf, increased hoxb13a expression was seen in both anal
and the tail regions at 5 dpf (Fig. 4B, C). This pattern of
elevated hoxb13a gene expression at 5 dpf was also evident
in embryos in which the RARg agonist was washed out at
23 hpf (data not shown). Moreover, data analysis of caudal
fin length also showed that both washout and RARg an-
tagonist treatment caused significant increase in caudal fin
length at 5 dpf compared with RARg-agonist-treated em-
bryos (Fig. 4D, E). Hence, these data suggest that the in-
hibitory effects of the RARg agonist on hoxb13a expression
and caudal fin formation were not due to early irreversible
teratogenic wherein hox gene expression was not possible.
Treatment with the RARc agonist caused changes
in head morphology, loss of anterior cranial bones,
and loss of anterior lateral line ganglia, but did not
affect the prevalence of Sox 9-immunopositive
neural crest cells
The head morphology of RARg-agonist-treated embryos
was markedly different from that of control embryos. At
3 dpf, there was a clear loss of the most anterior parts of the
FIG. 2. Treatment of embryonic zebrafish with a RARg agonist was associated with a reduction in somite formation. (A)
A representative fluorescence microscopy image showing the left lateral view of RARg-agonist-treated (10 nM) and control
hspGFF55B transgenic zebrafish embryos at 3 dpf where the somites are indicated by green fluorescent protein (GFP)
expression. There were five fewer somites present in the RARg-agonist-treated embryos (25 somites) compared with the
control embryos (30 somites), but there was no discernible difference in the size of the individual somites present, as shown
by counting from anterior somites 1–10. These differences were seen in every case of RARg-agonist-treated versus control
embryos (n= 3 independent experiments). (B, C) Representative bright-field images of in situ hybridization for myoD ex-
pression in the RARg-agonist-treated and control AB strain zebrafish embryos at 22 hpf, where a slightly reduced signal was
observed in somitic myoD expression in the RARg-agonist-treated embryos (myoD expression was determined in 14 RARg-
agonist-treated embryos versus 13 control embryos.). (D, E) Representative fluorescence microscopy images of a actinin
immunolocalization in RARg-agonist-treated and control AB strain zebrafish embryos at 3 dpf. No discernible differences in
immunopositivity were seen. An identically reduced number of somites as that seen in the hspGFF5B transgenic line, that is,
by five somites in RARg-agonist-treated embryos compared with control embryos at 3 dpf, was also seen in the RARg-agonist-
treated embryos immunostained for a actinin (immunostaining for a actinin was performed in 14 control and 14 RARg-
agonist-treated embryos.). Scale bars represent 250mm. Color images available online at www.liebertpub.com/scd
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head, that is, the primordia of the mouth and jawbone re-
gion, as well as an apparent loss of pharyngeal arches in the
RARg-agonist-treated embryos compared with control em-
bryos (Fig. 5A, B). Alizarin red staining of embryos at 5 dpf
confirmed a complete lack of anterior cranial bones, in-
cluding the maxillary, the hyomandibular, and the opercle
bones, as well as reduced formation of the cerebrobrachial
bones in RARg-agonist-treated embryos compared with con-
trol embryos (Fig. 5C, D). The HGn39D transgenic line was
used to examine neural tissues of the lateral line system within
the anterior regions of the head [23]. This analysis demon-
strated a loss of anterior lateral line ganglia in the RARg-
agonist-treated embryos at 3 dpf compared with controls at the
same time point (Fig. 5E), but no clear differences were seen
in either the posterior lateral line ganglia or the lateral line
itself. Immunolocalization of Sox9, which is a marker for
neural crest cells [31], showed that there was no clear differ-
ence in the prevalence of Sox9-immunopositive cells between
RARg-agonist-treated and control embryos at 25 hpf, but that
Sox9-immunopositive cells then decreased in number in the
anterior regions of the head in the RARg-agonist-treated em-
bryos only by 60 hpf (Fig. 6). Hence, RARg agonist treatment
was associated both with a loss of cranial neural crest stem/
progenitor cells as well as loss of the most anterior cranial
tissues that these cells form.
Treatment with the RARc agonist reversibly blocked
pectoral fin outgrowth
Although the pectoral fin bud was clearly present, RARg-
agonist-treated embryos did not grow the pectoral fin (Fig. 7A,
B). Immunolocalization for the transcription factor Tbx5a,
which is a marker of the lateral plate mesoderm stem/
progenitor cells that form the pectoral fin as well as the heart
FIG. 3. Differential patterns of hoxc11a and hoxb13a ex-
pression in transgenic reporter zebrafish embryos demonstrated
that the reduced axial length of RARg-agonist-treated embryos
was associated with loss of their most posterior regions. (A)
Representative fluorescence microscopy images showing GFP
expression in the hspGFF155A transgenic zebrafish reported
line for hoxc11a expression at 3 dpf, where a similar pattern of
expression was seen in the RARg-agonist-treated and control
embryos (n=3 independent experiments). (B) Representative
fluorescence microscopy images showing GFP expression in
the hspGFFDMC28B transgenic zebrafish reporter line for
hoxb13a expression at 3 dpf. In contrast to the control em-
bryos, RARg-agonist-treated embryos exhibited a complete
loss of GFP expression in the tail, as well as in the anal region
(arrows). The loss of hoxb13a expression was seen in every
RARg-agonist-treated hspGFFDMC28B transgenic zebrafish
embryos at 3 dpf (n=3 independent experiments). Scale bars
represent 250mm. Color images available online at www
.liebertpub.com/scd
FIG. 4. The effects of a RARg agonist on hoxb13a and
caudal fin outgrowth were reversed by agonist washout or
cotreatment with a RARg antagonist. Representative fluores-
cence microscopy image showing GFP expression in the
hspGFFDMC28B transgenic zebrafish reported line for hox-
b13a expression at 5 dpf, in which the embryos were treated
with RARg agonist at 4 hpf (A) or were treated with the ag-
onist at this time and then cotreated with the RARg antagonist
at 23 hpf (B, with higher magnification of the tail region shown
in C). Representative bright-field microscopy images show the
complete loss of the caudal fin in RARg-agonist-treated em-
bryos (inset A) and the extent to which the caudal fin had
grown in the embryos treated with the RARg antagonist (D).
(E) The graph shows the comparative length of the caudal fin
in the RARg-agonist-treated embryos versus the washout or
RARg-antagonist-cotreated embryos at 5 dpf. Data are shown
as means–SDs, pooled from four independent experiments.
Scale bars represent 250mm. Color images available online at
www.liebertpub.com/scd
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FIG. 5. Treatment of zebrafish embryos with a RARg agonist was associated with loss of cranial tissues derived from the
neural crest. (A, B) Representative phase-contrast microscopy images showing head morphologies in RARg-agonist-treated
and control AB strain embryos at 3 dpf. The pharyngeal arches were visible in the control embryos only. (C, D)
Representative bright-field microscopy images of alizarin red S-stained AB strain embryos showing that all of the cranial
bones were absent in RARg-agonist-treated embryos at 5 dpf except for the most posterior part of the cerebrobranchial 5
(cb5) bone and the cleithrum (cl) bones. Other bones labeled are as follows: hyomandibular (hym), maxillary (max), and
opercle (op). All of the control embryos showed normal cranial bones, while all of the RARg-agonist-treated embryos
showed a loss of cranial bones at 5 dpf (n = 3 independent experiments). (E) A representative confocal microscopy image of
the transgenic zebrafish HGn39D reporter line, demonstrating the specific loss of GFP signal in the anterior lateral line
ganglia (alg) of RARg-agonist-treated embryos only at 3 dpf, but not in the posterior lateral line ganglia (plg) or the lateral
line (ll) itself, all of which were evident in control embryos at the same stage. All the control HGn39D transgenic zebrafish
embryos had intact anterior later line ganglions, while all of the RARg-agonist-treated HGn39D transgenic zebrafish
embryos showed loss of anterior lateral line ganglions (n = 3 independent experiments). Scale bars represent 250 mm. Color
images available online at www.liebertpub.com/scd
FIG. 6. Treatment of zebrafish embryos with a RARg agonist was associated with loss of Sox9-immunopositive cranial
neural crest stem/progenitor cells. (A–D) Representative confocal-microscopy-projected images of z stacks through the
entire lateral perspective of AB strain zebrafish following Sox9 immunolocalization are shown. Sox9 immunopositivity was
observed in the developing pharyngeal arches (pa) of control embryos only at 60 hpf (arrows in C), but were not seen in
RARg-agonist-treated embryos. A similar number of Sox9-immunopositive pictures was seen in RARg agonist and control
embryos at 25 hpf (A, B). However, reduced numbers of Sox9-immunopositive cells were observed in the RARg-agonist-
treated embryos at 60 hpf compared with the control embryos (C–E). Data are shown as means – SDs, pooled following
immunostaining and scores of three control and six RARg-agonist-treated embryos (P £ 0.05; Mann–Whitney U test). Scale
bars represent 250mm. Color images available online at www.liebertpub.com/scd
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[32,33], showed that Tbx-5-immunopositive cells were present
in these regions in both the RARg-agonist-treated and the
control embryos at 27 hpf (Fig. 7C, D), which is the time point
when pectoral fin outgrowth commences [33]. Hence, there
was no loss of lateral plate mesodermal stem/progenitor cells
associated with the effects of the RARg agonist on the pectoral
fin, or, indeed, the development of cardiac edema. Embryos
were treated with the RARg agonist from 4 hpf and then the
medium containing the RARg agonist was either replaced with
control media (ie, washout) or the same concentration (10 nM)
of the RARg antagonist was added at 27 hpf. In both of these
experiments, subsequent pectoral fin outgrowth was observed
at 3 dpf (Fig. 7E, F). In contrast, when the control embryos
were treated with the RARg agonist at 27 hpf, pectoral fin
outgrowth was subsequently completely blocked (Fig. 7G).
Therefore, treatment with the RARg agonist was associated
with a reversible block in pectoral fin formation, which was
independent of Tbx5 expression.
Treatment with the RARc agonist reversibly blocked
caudal fin regeneration
RARg is expressed in the caudal regions of the devel-
oping zebrafish [9,10] and again during adult caudal fin
regeneration after transection [34]. The caudal fin in larval
zebrafish can regenerate within 3 days after fin transection at
2 dpf [35]. Therefore, we performed experiments to examine
whether RARg agonist treatment also affected caudal fin
regeneration in zebrafish larvae. Caudal fin regeneration,
following transection at 2 dpf, was observed in control
embryos at 5 dpf (Fig. 8A). In contrast, the regeneration
process was completely blocked when the embryos were
treated with the RARg agonist immediately following fin
transection (Fig. 8B). When treatment with the RARg ago-
nist immediately following fin transection at 2 dpf subse-
quently followed with the addition of the RARg antagonist
(10 nM) or by washout of the RARg agonist at 24 h post-
transection, then fin regeneration was again observed at
5 dpf (Fig. 8C, D).
Canonical Wnt signaling has been reported as important
to blastema formation during zebrafish caudal fin regener-
ation [36]. The upregulation of canonical Wnt signaling
during adult caudal fin regeneration is observed in the
Tcf:mini-p reporter zebrafish line, in which GFP expression
is driven by the engagement of b catenin with the Tcf re-
porter [24]. However, the involvement of canonical Wnt
signaling in larval fin regeneration has not been reported.
Canonical Wnt signaling in caudal fin rays during normal
FIG. 7. Treatment of zebrafish embryos with a RARg agonist was associated with a reversible block in pectoral fin
outgrowth with no evident changes in loss of Tbx5 expression in the lateral plate mesoderm at 27 hpf. (A, B) Representative
phase-contrast microscopy images showing normal outgrowth of the pectoral fin in control AB strain embryos at 3 dpf and
the complete loss of pectoral fin outgrowth that was observed in RARg-agonist-treated embryos at the same time point. All
the control embryos showed normal pectoral fin outgrowth, while all the treated embryos showed loss of pectoral fin
outgrowth at 3 dpf (n = 3 independent experiments). (C, D) Representative confocal-microscopy-projected images of z
stacks through the entire lateral perspective of AB strain zebrafish following Tbx5 immunolocalization. As shown, a similar
distribution of Tbx5 immunopositivity was seen in the lateral plate mesoderm and heart regions (both arrows) at 27 hpf in
the RARg-agonist-treated and control embryos (following immunostaining in 10 control and 10 RARg-agonist-treated
embryos). (E–G) Representative phase-contrast microscopy images are shown. Pectoral fin outgrowth in AB strain embryos
that had been treated with the RARg agonist at 4 hpf was restored by (E) washing out the RARg agonist at 27 hpf. All the
RARg-agonist-treated embryos which agonist was washed out 27 hpf showed pectoral fin regrowth (n = 3 independent
experiments) or (F) adding an equal dose (10 nM) of the RARg antagonist at 27 hpf. All the RARg-agonist-treated embryos
which agonist was added antagonist at 27 hpf showed pectoral fin regrowth (n = 2 independent experiments). (G) Con-
versely, pectoral fin outgrowth in control embryos was completely blocked when control media were replaced with the
RARg agonist supplemented media at 27 hpf. All of the control embryos that were subsequently treated with RARg agonist
at 27 hpf showed a loss of pectoral fin regrowth (n = 3 independent experiments). Scale bars represent 250mm. Color images
available online at www.liebertpub.com/scd
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development was not evident using the reporter fish line by
4 dpf (Fig. 8E). In contrast, following caudal fin transection
at 3 dpf, increased canonical Wnt signaling was observed in
the regenerating blastema at 4 dpf (Fig. 8G). This increased
Wnt signal at 4 dpf was not observed in zebrafish embryos
that were transected at 3 dpf and immediately treated with
the RARg agonist (10 nM), although there was an evident
increase in signal in the notochord (Fig. 8F). Therefore,
treatment with the RARg agonist was associated with a re-
versible block in caudal fin regeneration, which was asso-
ciated with decreased canonical Wnt signaling.
Discussion
This study was performed to examine the potential role of
RARg in regulating embryonic development and tissue re-
generation using wild-type and gene reporter embryonic
zebrafish as model systems. We demonstrated that treatment
of embryonic zebrafish with a RARg-specific agonist had
profound developmental consequences, including decreased
antero-posterior growth, inhibition of cranial bone and
neural tissue formation, and loss of growth of the pectoral
and caudal fins, as well as abrogation of caudal fin regen-
eration following fin transection. We also noted that RARg-
agonist-treated fish exhibited cardiac edema. These findings
strongly suggest that RARg activity must be tightly regu-
lated during normal embryonic development and tissue re-
generation.
The tissues that were affected by treatment with the
RARg agonist derive from those stem/progenitor cell pop-
ulations in which RARc expression is restricted during early
embryonic development, that is, in the cranial neural crest,
in the lateral plate mesoderm, and in the presomitic meso-
derm of the tail bud [9,10]. In addition, the tissues affected
by the RARg agonist also mirror those that are similarly
affected by morphilino gene knockdown of RARc (a and b),
namely, the pharyngeal arches and pectoral and caudal fins
[37]. Further, this phenotype is similar to the effects of RA
treatment on embryonic development [38]. Taken together,
this suggests that the agonist used in the current study was
specific for RARg in zebrafish, as it has been conclusively
demonstrated in mammalian reporter cell lines [15].
The mechanisms involved in the developmental changes
observed have been examined using a combination of
transgenic reporter fish lines, in situ hybridization and im-
munohistology for several important genes, and appropriate
stem/progenitor cell markers. The shorter body axis for-
mation seen in RARg-agonist-treated embryos was associ-
ated with decreased somite formation, as revealed in
hspGFF55B transgenic embryos and a-actinin immuno-
localization. The differential expression of the hox gene
family plays an essential role in formation of the antero-
posterior axis during vertebrate embryonic development
[30]. Hence, we examined the effects of the RARg agonist
on transgenic hox gene reporter fish lines. Analysis of the
hoxc11a and hoxb13a reporter lines demonstrated that the
FIG. 8. Treatment of zebrafish embryos with a RARg agonist was associated with a reversible block in caudal fin
regeneration and decreased canonical Wnt signaling. (A, B) Representative phase-contrast microscopy images show caudal
fin regeneration in AB strain control embryos, but not in RARg-agonist-treated embryos, when the embryos were RARg
agonist treated at the same time as fin transection. All of the transected fins in control embryos showed fin regeneration,
while none of the transected fins in RARg-agonist-treated embryos showed fin regenerated at 5 dpf (n = 3 independent
experiments). (C, D) Representative phase-contrast microscopy images are shown. Caudal fin regeneration was restored in
RARg-agonist-treated embryos by either (C) washing out the RARg agonist at 1 day post-transection or (D) adding an equal
dose (10 nM) of the RARg antagonist at 1 day post-transection. These findings were consistent in all embryos (n = 2
independent experiments). (E–G) Representative fluorescence microscopy images of canonical Wnt signaling in the
transgenic zebrafish Tcf:mini-p reporter line. (E) Little GFP expression to indicate canonical Wnt signaling was seen in the
caudal tail of nontransected zebrafish embryos at 4 dpf. (F) In contrast, there was a marked upregulation in GFP expression,
demonstrating increased canonical Wnt signaling in the regenerating caudal fins of control embryos at the same time point,
that is, at 4 dpf and 1 day after transection (white arrows). (G) No GFP-evident canonical Wnt signaling was seen in the
transected fins of the RARg-agonist-treated embryos at 4 dpf and 1 day after transection. These embryos did not regenerate
transected caudal fins. However, increased canonical Wnt signaling was seen in the notochord (yellow arrow). These
different patterns of Wnt signaling were seen consistently in all embryos (n = 3 independent experiments). Scale bars
represent 250mm. Color images available online at www.liebertpub.com/scd
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shorter body axis was largely the result of loss of the most
posterior region of the embryos. Hoxc11 is developmentally
expressed in the posterior region of the mouse embryo [39]
and homozygous knockout of the hoxc cluster results in loss
of caudal vertebrae [30,40]. In mice, hoxb13 expression
occurs in the tail bud area around E9 [41]. Hoxb13 ex-
pression is also found in the developing tail of axolotl and
re-expressed in the regenerating tail after transection [42].
These expression patterns suggest that hoxb13 plays an
important role in the development and growth of the tail.
Conversely, a heterozygous knockout of hoxb13 in mice was
shown to cause overgrowth of the tail [43]. Our observation
of a complete loss of hoxb13a expression in RARg-agonist-
treated zebrafish supports the hypothesis that this gene is
essential for the formation of the posterior regions of de-
veloping embryos and may be regulated by RARg. Extra-
somitic expression of hoxb13a was also seen in the anal fin
area of the control embryos, which was completely lost in
the RARg-agonist-treated embryos. Other researchers have
similarly reported Hoxb13 expression in the hindgut and
urogenital area of mice [41]. Hence, our observation further
suggests that treatment with the RARg agonist targeted the
expression of hox genes in the posterior regions of the
zebrafish embryos, particularly hoxb13a expression, in that
no expression was seen following such treatment. We can-
not exclude the possibility that hoxb13a expression may
have been absent from the RARg-agonist-treated embryos
because the tissues in which hoxb13a is normally expressed
during development, including the anal area, were not
formed. However, the re-expression of hoxb13a in both the
anal region and tail region in embryos that were treated at
4 hpf with the RARg agonist, but then subsequently were the
RARg agonist was washed out or the embryos were addi-
tionally treated with the RARg antagonist, which was also
associated with evident renewed growth of the caudal fin,
would suggest that at least such a loss of tissue formation is
acutely responsive to the presence of reagents that affect
RARg. The loss of hox gene expression in response to
treatment with a RAR agonist is certainly paradoxical as
RARE is located within the regulatory region of hox gene
clusters [44], which are normally upregulated in response to
RA [45–47]. Such a paradox may be resolved if RARg does
not require RA or indeed does not function through RARE
to regulate target gene expression.
The marked morphological changes seen in the head of
the RARg-agonist-treated embryos were associated with
loss of cranial bones and the anterior lateral line ganglia as
revealed by alizarin red staining and the HGn39D transgenic
fish line, respectively. These tissues form from the neural
crest, as well as the placode for the lateral line [48]. This
suggests that RARg agonist treatment may have targeted
neural crest stem/progenitor cells, which are known to ex-
press RARg [9,10]. The fact that we saw significantly fewer
Sox9-immunopositive cells in the cranial region of the
RARg-agonist-treated embryos might be considered to
support this hypothesis. However, this difference was only
seen in later time points, that is, at 60 hpf but not at 25 hpf,
even though RARg is expressed at the earlier time point.
Further, even at 60 hpf, Sox9-immunopositive cells were
still observed in the cranium. Therefore, it is also possible
that fewer Sox9-immunopositive cells were prevalent within
the anterior cranial regions of the RARg-agonist-treated
embryos simply because the anterior tissues did not form.
Further research is required to examine whether the loss of
Sox9 neural crest stem/progenitor cells following treatment
with the RARg agonist is causal to the loss of anterior
cranial tissues observed. However, it is noteworthy that
Sox9a or Sox9b morphilino knockdown and Sox9a mutant
zebrafish embryos were shown to lack cranial skeletal
structures [49,50]. These developmental defects were asso-
ciated with Sox9 aberrant neural crest stem/progenitor cell
differentiation, rather than any changes in neural crest for-
mation or cell migration. Similarly, we conclude that
treatment with the RARg agonist did not markedly affect the
formation of neural crest stem/progenitor cells, as depicted
by Sox9-immunopositive cells at 25 hpf, but may well have
influenced their survival, proliferation, migration, or dif-
ferentiation thereafter, to adversely affect the development
of cranial tissues.
Although almost all of the neural-crest-derived cranial
bones were absent or greatly decreased in the RARg-
agonist-treated embryos, there were still fully intact clei-
thrum bones, which also are of neural crest origin [51].
There is no clear explanation for this difference. However, it
is interesting that cleithrum bones undergo a process of
dermal ossification, unlike other affected cranial bones that
undergo endochondral ossification [51,52].
An additional major phenotype seen following treatment
with the RARg agonist was the loss of pectoral fin out-
growth, despite formation of the fin bud. Other studies have
reported that the interaction of RA signaling with expression
of Tbx5a transcription factor is essential for pectoral fin
formation. Increased raldh1a2 expression and its localized
synthesis of RA in the region of somites two to six, where
Tbx5a expression is induced in response to RA, is required
for formation of the pectoral fin [32]. Both the Nls
(neckless)–mutant zebrafish, which carries a mutation in
raldh1a2 [16], and embryonic zebrafish treated with the RA
synthesis inhibitor diethylaminobenzyldehyde (DEAB) do
not express Tbx5a and do not form pectoral fins [53].
Moreover, loss-of-function Tbx5a mutations block pectoral
fin formation, as well as causing heart defects [54]. Zebra-
fish Tbx5a expression can be seen from 14 hpf in the lateral
late mesoderm, which is the common stem/progenitor cell
population for development of the heart and pectoral fins
and separate from 24 to 27 hpf [33]. Because the pectoral
fins did not form in the RARg-agonist-treated embryos in
our study, Tbx5 was considered a potential target gene for
RARg agonism. However, we found no marked differences
in the presence of Tbx5a-immunopositive stem/progenitor
cells in the RARg-agonist-treated or control embryos, sug-
gesting that Tbx5a expression was unaffected. Further,
RARg-agonist-washout experiments or cotreatment with a
RARg-specific antagonist (as well as the agonist) com-
pletely abrogated the block of pectoral fin formation, dem-
onstrating that Tbx5 was functional. Finally, treatment with
the RARg agonist at 27 hpf, which we had confirmed was
when Tbx5 was present in the lateral plate mesoderm, was
also found to completely block pectoral fin outgrowth.
Therefore, we conclude that the effect of RARg agonist
treatment on pectoral fin outgrowth was independent of
Tbx5. Potential targets that lie downstream of Tbx5 activity
include fgf family genes, that is, fgf8, fgf10, and fgf24
[55,56], as well as sall4 [57], blimp-1 [58], prdm1 [59],
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beta-CaMK-II [60], and ndrg4 [61]. In addition, hox gene
expression was also associated with pectoral fin formation,
including hoxa [62], hoxb [63], and hoxd [64,65]. Further
study will elucidate whether RARg agonist treatment alters
the expression of each of these genes, but given our finding
that hoxb13a was completely inhibited by such treatment,
this family is a clear target.
Lastly, we tested whether the RARg agonist affected
tissue regeneration as well as development using transection
of the caudal fin as a model because RARg is expressed in
blastemal cells at least during adult zebrafish caudal fin
regeneration [34]. Similar to our findings with pectoral fin
outgrowth, we found that RARg agonist treatment was as-
sociated with a complete, but reversible, block on caudal fin
regeneration. Canonical Wnt signaling is known to play a
major role in caudal fin regeneration [36]. Therefore, we
investigated whether this pathway was affected by treatment
with the RARg agonist using the transgenic reporter line
Tcf:mini-p [24]. As we hypothesized, the block in caudal fin
regeneration following RARg agonist treatment was associated
with an observed reduction in Wnt signaling, suggesting that
the Wnt pathway is a target for RARg. However, similarly to
our observations of Sox9-immunopositive cells in the cranial
neural crest, there is also the possibility that Wnt signaling was
not seen following transection of the caudal fin and treatment
with the RARg agonist because the regenerating tissues did not
form. Therefore, further study is required to determine whether
the evident loss of Wnt signaling following RARg agonist
treatment is causal to the lack of a regenerative response.
In summary, our results have shown that treatment of
zebrafish embryos with a RARg-specific agonist adversely
affected the development and growth of tissues that form
from stem/progenitor cells that express RARg [9,10,34].
These stem/progenitor cell zones [4,32,66] do not express
RA-synthesizing enzymes [16,17] and are not exposed to
intrinsic RA [18]. This suggests that RARg functions in the
absence of RA ligation. The function of non-RA-ligated
RARs is not clear. In mice, RARs were considered to re-
press gene expression through corepressor activity in the
absence of RA ligation [8,14]. However, it has been reported
that RARs in zebrafish may not have such corepressor ac-
tivity [67]. What is clear is that RARg plays an essential role
during embryonic development and likely regulates stem/
progenitor cell populations. Similar to our results using a
RARg agonist, RARg morphilinos were found to adversely
affect the formation of cranial tissue, pectoral fin outgrowth,
and the caudal tail [37]. Moreover, in somatic cell repro-
gramming, RARg overexpression was related to the rate and
efficiency of reprogramming to induced pluripotency [68].
This was suggested to indicate that RARg functions to
maintain pluripotent stem cell populations. Although the
exact function of RARg is still not clear, based on our
current findings we concur with this hypothesis and further
suggest that such activity is seen only when RARg is non-
ligated.
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